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KEY POINTS
 All patients with ulcerative colitis (UC) and Crohn’s colitis should be offered a screening
colonoscopy 8 to 10 years after onset of disease symptoms to restage extent of disease
and evaluate for endoscopic features that confer an increased risk for inflammatory bowel
disease–associated colorectal neoplasia (IBD-CRN).
 Surveillance colonoscopy should be offered to UC patients with left-sided or extensive
colitis (thus excluding patients with isolated proctitis), and for patients with Crohn’s colitis
involving more than 1 segment of the colon or at least one-third of the colon.
 Patients with the highest risk of IBD-CRN should undergo annual surveillance. Lower-risk
patients can undergo surveillance at less frequent intervals, every 2 to 5 years.
 European and Australian guidelines agree that dye-based chromoendoscopy with
targeted biopsies maximizes detection of colorectal neoplasia during surveillance colo-
noscopy, and is the surveillancemethod of choice. Most United States guidelines endorse
chromoendoscopy with targeted biopsy as an option for surveillance.
 Endoscopically visible lesions that are well circumscribed and amenable to endoscopic
resection with no evidence of dysplasia in the surrounding flat mucosa or elsewhere in
the colon are appropriate for continued colonoscopic surveillance.INTRODUCTION
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Shergill & Farraye470gastrointestinal (GI) societies.1–8 The goal of endoscopic surveillance is to reduce the
morbidity and mortality of CRC, by either detecting and resecting dysplasia or detect-
ing CRC at earlier, potentially curable stages.9 Randomized controlled trials (RCTs)
assessing the efficacy of surveillance colonoscopy in IBD have not been performed,
and likely will not be performed.6 Case series, case-control studies, and population-
based cohort studies suggest that use of surveillance colonoscopy is associated
with an earlier stage of cancer diagnosis and improved CRC-related survival in IBD pa-
tients.10–14 Although a Cochrane analysis from 2006 concluded that there is no clear
evidence that surveillance colonoscopy prolongs survival in patients with extensive co-
litis,15 a subsequent cohort study of 149 patients with IBD-associated CRC from the
Netherlands, not included in the Cochrane analysis, found a 100% 5-year survival of
23 patients enrolled in a surveillance program before CRC detection, compared with
74% in a nonsurveillance group (P 5 .042).14 Of 30 CRC-related deaths during the
study period (January 1, 1990 to July 1, 2006), only 1 patient was in the surveillance
group compared with 29 in the nonsurveillance group (P 5 .047). It was also noted
that 52% of patients in the surveillance group had Stage 0 to 1 CRC, compared with
24% in the nonsurveillance group (P 5 .004).14 In an exploratory cost-effectiveness
model performed by the National Institute for Health and Clinical Excellence (NICE),
colonoscopy surveillance was determined to be cost-effective for high-risk groups,
which included IBD patients with any history of dysplasia, extensive active colitis,
primary sclerosing cholangitis (PSC), strictures within the last 5 years, or family history
of CRC before 50 years of age.6
Thus, surveillance colonoscopy in patients with ulcerative colitis (UC) and Crohn’s
colitis has been recommended by multiple societies in the United States (American
Gastroenterological Society [AGA],2 American Society for Gastrointestinal Endoscopy
multiple European societies (British Society for Gastroenterology [BSG],1 NICE,6 Euro-
pean Crohn’s and Colitis Organization [ECCO]7), the [ASGE],5 American College of
Gastroenterology [ACG],4 Crohn’s and Colitis Foundation of America [CCFA],3 multiple
European societies [British Society for Gastroenterology (BSG),1 NICE,6 European
Crohn’s and Colitis Organization (ECCO)],7 the Cancer Council of Australia [CCA],8
the New Zealand Guidelines Group,16 and the North American Society for Pediatric
Gastroenterology, Hepatology and Nutrition [NASPGHN]).17 However, recommenda-
tions differ in regards to timing of initial screening colonoscopy, recommended surveil-
lance intervals, optimal technique for dysplasia detection, and management of
detected lesions and endoscopically invisible dysplasia. This article reviews current
society guidelines, highlighting similarities and differences, in an attempt to form a gen-
eral consensus on surveillance for patients with IBD, while drawing attention to contro-
versial areas in need of further research.WHO SHOULD BE OFFERED SCREENING AND SURVEILLANCE FOR IBD-ASSOCIATED
CRC?
Most societies agree that all patients with a history of UC (even isolated proctitis) and
Crohn’s colitis should be offered a screening colonoscopy approximately 8 to 10 years
after the onset of clinical symptoms to re-stage extent of disease and evaluate for
endoscopic features that confer a higher risk for IBD-associated CRN (IBD-CRN).
The exception is the NICE guideline,6 which recommends only offering colonoscopic
surveillance to patients with Crohn’s colitis involving more than 1 segment of the colon
or left-sided or more extensive UC, but not isolated ulcerative proctitis. All societies
recommend that patients with PSC and UC should be enrolled in a surveillance
program at the time of diagnosis.
Surveillance of Patients with Colonic IBD 471During the initial screening examination, restaging biopsies are recommended to
determine disease extent and severity. The extent of disease is defined by the
maximum documented extent of disease on any colonoscopy. All societies recom-
mend surveillance colonoscopy for UC patients with left-sided or extensive colitis
(thus excluding patients with isolated proctitis),1–6,8 and for Crohn’s colitis involving
more than 1 segment of the colon6,18 or at least one-third of the colon.2,3,5,8 The
BSG considers patients with Crohn’s disease of less than 50% of colonic involvement,
regardless of grade of inflammation, as lower risk, but does offer surveillance at the
longest (5-year) intervals.1 The ACG guidelines recognize the possible increased
risk of cancer in long-standing Crohn’s disease, but state that surveillance guidelines
have yet to be defined, and do not endorse a screening or surveillance strategy.19
Guidelines Summary
 All patients with UC and Crohn’s colitis should be offered a screening colonos-
copy to restage the extent of disease and evaluate for endoscopic features
that confer a higher risk for IBD-CRN.
 Surveillance colonoscopy should be offered for UC patients with left-sided or
extensive colitis (thus excluding patients with isolated proctitis), and for Crohn’s
colitis involving more than 1 segment of the colon or at least one-third of the
colon.WHEN SHOULD SCREENING BE INITIATED?
Current guidelines base screening for IBD-CRN primarily on duration of disease. The
risk of IBD-CRN increases over time, although estimates of risk vary in the literature.
Meta-analysis of older studies estimated an increase in risk over time, with a cumu-
lative CRC risk of 2% at 10 years, 8% at 20 years, and 18% after 30 years of coli-
tis.20 More recent population-based studies have demonstrated a lower overall risk,
from 2.5% at 20 years, to 7.6% at 30 years, and 10.8% at 40 years of extensive
UC.21
These studies support initiating screening by 10 years of symptom onset, as recom-
mended by the BSG1 and NICE,6 with most societies recommending initiating
screening at 8 years2,8,18 or 8 to 10 years3–5 after symptom onset. However, recent
population-based studies demonstrating that 17% to 35%22–24 of patients develop
CRC before 8 to 10 years has prompted some societies to recommend earlier
screening colonoscopy. The NASPGHN recommends initiation of screening 7 to
10 years after diagnosis.17 The 2012 Second European evidence-based consensus
on the diagnosis and management of UC states that screening could be initiated 6
to 8 years after symptom onset, taking into consideration risk factors such as extent
and severity of disease, history of pseudopolyps, family history, and age at onset.7
These recent studies demonstrating early IBD-CRN occurrence underscore the
need for considering additional risk factors to optimize initiation of IBD-CRN
screening. Risk stratification based on age at disease onset (both young age and older
age appear to confer increased risk23,25), extent and severity of disease, family history,
and pseudopolyps has been advocated by some of the societies, and is in need of
further study for incorporation into the IBD surveillance guidelines.
Guidelines Summary
 Most society guidelines recommend initiating surveillance 8 to 10 years after
disease onset; some recommend considering risk factors that may increase
the risk for IBD-CRN, and warrant earlier surveillance.
Shergill & Farraye472HOW OFTEN SHOULD SURVEILLANCE COLONOSCOPY BE PERFORMED?
Optimal surveillance intervals have not been defined in prospective studies, and the
societies differ on their recommended surveillance intervals after the index screening
colonoscopy. In general, patients with the highest risk of IBD-CRN are recommended
for annual surveillance, whereas patients with the lowest risk are recommended for
less frequent surveillance intervals, varying from 2 to 5 years.
Risk factors for IBD-CRN include concomitant PSC, extensive colitis, active endo-
scopic or histologic inflammation, a family history of CRC in a first-degree relative
before 50 years of age, personal history of dysplasia, presence of strictures on colo-
noscopy, and, possibly, gender (Table 1). With the exception of gender, all recent
guidelines recommend annual surveillance for individuals with these high risk features
(AGA, BSG, NICE, ECCO, CCA).
Normal-appearing mucosa on surveillance appears to be associated with a
decreased risk of IBD-CRN, reduced to approximately that of the general popula-
tion.34 The United States GI societies have not yet endorsed lengthening surveillance
intervals beyond 3 years. BSG, ECCO, NICE and CCA recommend a risk-stratified
approach to cancer surveillance, and increase the surveillance interval to 5 years in
the lowest-risk patients (Table 2).
Severe active inflammation, prior dysplasia, and strictures are universally accepted
as high-risk endoscopic features. Whereas the CCA8 suggests annual examinations
for patients with multiple pseudopolyps and shortened colons, the BSG1 and the
ECCO18 guidelines consider these patients for colonoscopies every 2 to 3 years.
The CCA8 allows for a 5-year interval for surveillance in patients with 2 prior macro-
scopically and histologically normal colonoscopies, whereas the NICE6 and BSG1
consider patients with left-sided UC or Crohn’s disease of similar extent, regardless
of degree of inflammation, appropriate for 5-year surveillance.Table 1
Risk factors for IBD-CRN
Risk Factor Risk of IBD-CRN Authors,Ref. Year
PSC OR 4.09, 95% CI 2.89–5.67 Soetikno et al,26 2002
Extensive colitis Pancolitis associated with a SIR
5.6–14.8 compared with the
general population
Ekbom et al,27 1990
Soderlund et al,28 2009
Beaugerie et al,24 2013
Active endoscopic inflammation OR 2.54, 95% CI 1.45–4.44 Rutter et al,29 2004
Active histologic inflammation OR 5.13, 95% CI 2.36–11.14 Rutter et al,29 2004
OR 2.56, 95% CI 1.45–4.54 Rubin et al,30 2013
HR 3.0, 95% CI 1.4–6.3 for mean
inflammatory score
Gupta et al,31 2007
Family history of CRC <50 y old RR 9.2, 95% CI 3.7–23 Askling et al,32 2001
Personal history of dysplasia LGD: 12-fold increased risk of
developing advanced neoplasia
and 9-fold increased risk of
developing CRC
Thomas et al,33 2007
Strictures on colonoscopy OR 4.62, 95% CI 1.03–20.8 Rutter et al,34 2004
Gender Men: SIR 2.6, 95% CI 2.2–3.0
Women: SIR 1.9, 95% CI 1.5–2.3
Jess et al,25 2012
Abbreviations: CI, confidence interval; CRC, colorectal cancer; HR, hazard ratio; IBD-CRN, inflam-
matory bowel disease–associated colorectal neoplasia; LGD, low-grade dysplasia; OR, odds ratio;
PSC, primary sclerosing cholangitis; RR, relative risk; SIR, standardized incidence ratio.
Table 2
Risk-stratified approach to IBD-CRN surveillance
Every Year: High Risk Every 3 Years: Intermediate Risk Every 5 Years: Low Risk
BSG,1 2010 Moderate or severe endoscopic/histologic
active inflammation
Stricture within the past 5 y
Confirmed dysplasia within the past 5 y in
a patient who declines surgery
PSC
Family history of CRC in first-degree
relative <50 y
Mild endoscopic/histologic inflammation
Presence of postinflammatory polyps
Family history of CRC in first-degree
relative >50 y
No endoscopic/histologic active inflammation
(histologic chronic or quiescent changes
acceptable)
Left-sided colitis (any grade of inflammation)
Crohn’s colitis affecting <50% surface area of
the colon (any grade of inflammation)
NICE,6 2011 Extensive ulcerative or Crohn’s colitis with
moderate or severe active inflammation
PSC
Colonic strictures in the past 5 y
Any grade of dysplasia in the past 5 y
CRC in first-degree relative <50 y
Extensive ulcerative or Crohn’s colitis with
mild active inflammation
Postinflammatory polyps
CRC in first-degree relative >50 y
Left-sided UC or Crohn’s colitis of similar extent
Extensive but quiescent UC/Crohn’s colitis
ECCO,18 2013 Stricture or dysplasia detected within past 5 y
PSC
Extensive colitis with severe active
inflammation
CRC in first-degree relative <50 y
Every 2–3 y recommended
Extensive colitis with mild or moderate
active inflammation
Postinflammatory polyps
CRC in first-degree relative >50 y
Neither intermediate- nor high-risk features
CCA,8 2011 Active disease
PSC
CRC in first-degree relative <50 y
Colonic stricture
Multiple postinflammatory polyps or
shortened colon (endoscopic features of
prior severe inflammation)
Previous dysplasia
Inactive UC or Crohn’s colitis affecting
more than one-third of the colon
without any high-risk features
CRC in first-degree relative >50 y
Two prior colonoscopies that were
macroscopically and histologically normal
A minimum of 1 factor is needed to meet criteria defined as high, intermediate, or low risk.
Abbreviations: BSG, British Society for Gastroenterology; CCA, Cancer Council of Australia; ECCO, European Crohn’s and Colitis Organization; NICE, National
Institute for Health and Clinical Excellence (UK); UC, ulcerative colitis.
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Shergill & Farraye474Further study is needed to determine which endoscopic features confer the greatest
risk of IBD-CRN, and whether limited inflammation or no inflammation is associated
with the lowest risk of IBD-CRN. Additional consensus is needed on how to risk-
stratify patients and the optimal surveillance intervals for high-, intermediate-, and
low-risk patients, as these questions will likely not be answered in prospective studies.
Guidelines Summary
 Patients with the highest risk of IBD-CRN, which includes patients with UC and
Crohn’s colitis with active extensive disease, PSC, prior history of stricture or
dysplasia, or a first-degree relative with CRC before the age of 50, should un-
dergo annual surveillance. Lower-risk patients can undergo surveillance at inter-
vals of every 2 to 5 years.WHAT IS THE RECOMMENDED TECHNIQUE FOR DYSPLASIA DETECTION?
The goal of surveillance colonoscopy is detection of CRN at its earliest, curable
stages. Historically, dysplasia in IBD was thought to be completely flat and endoscop-
ically undetectable, and random biopsies were recommended for dysplasia detection.
One prospective study using a 4-quadrant random biopsy protocol every 10 cm calcu-
lated that if dysplasia was present in 5% of the colonic mucosa, 33 biopsies were
required for histologic detection of dysplasia with 90% confidence.35 This standard
was then endorsed by multiple societies.
Subsequent studies demonstrated that most dysplasia is in fact endoscopically
visible, and that random biopsies are overall of low yield in comparison with targeted
biopsies of endoscopically abnormal-appearing mucosa.36–39 Lesion detection is
enhanced with dye-based chromoendoscopy using indigo carmine or methylene
blue, as demonstrated in multiple RCTs. A recent meta-analysis calculated that chro-
moendoscopy with targeted biopsy is 8.9 times more likely to detect any dysplasia
and 5.2 times more likely to detect nonpolypoid dysplasia than white-light endoscopy
with random biopsy.40 The likelihood to miss dysplasia was 93% lower in colonoscop-
ies performed with chromoendoscopy and targeted biopsy than with white-light and
random biopsy, with a number-needed-to-test of 14 to detect 1 additional patient
with dysplasia.40
Other techniques for image enhanced endoscopy are under investigation, but data
currently do not support their routine use.9,18,41,42 Narrow-band imaging has not
demonstrated an increased yield for dysplasia detection during surveillance examina-
tions when compared with chromoendoscopy or white-light endoscopy. Confocal
laser endomicroscopy may have a role in the characterization of dysplasia once
detected, but additional studies are needed.42
At present, chromoendoscopy with targeted biopsies is the surveillance protocol of
choice as endorsed by all recent European guidelines (BSG, NICE, ECCO),1,6,18 with
the ECCO group further stating that, “if appropriate expertise for chromoendoscopy
is not available, random biopsies should be performed; however this is inferior to chro-
moendoscopy in the detection rate of neoplastic lesions.”18 Societies in the United
States have taken amore conservative approach. The CCFA 20043 guidelines endorse
chromoendoscopy in appropriately trained endoscopists. The AGA 20102 guidelines
state that chromoendoscopy with targeted biopsies is a reasonable alternative to
white-light endoscopy for endoscopists experienced in this technique. The ACG
20104 guidelines state that the natural history of dysplastic lesions detected by chro-
moendoscopy is unknown, and that it is premature to endorse chromoendoscopy in
low-risk patients without longer-term follow-up data. However, chromoendoscopy
Surveillance of Patients with Colonic IBD 475may be of value for the follow-up of “higher-risk” patients, such as those with known
dysplasia or indefinite for dysplasia not undergoing colectomy, and to ensure that
detected lesions are adequately resected. The ASGE IBD guidelines are currently un-
der revision, but the recently published ASGE tissue-sampling guidelines43 endorse
chromoendoscopy with targeted biopsies as an option to optimize dysplasia detection
with standard white-light endoscopy when the expertise is available.
The BSG, NICE, and ECCO guidelines, while endorsing chromoendoscopy with tar-
geted biopsies as the preferred surveillance technique, further state that the yield of
random biopsies of normal-appearing mucosa is low.1,6,18 The CCA recommends
obtaining histologic staging biopsies, as histologic inflammation is a risk factor for
IBD-CRN and is used for risk stratification, but do not definitively state that random
biopsies are not required.8 The CCA guidelines recommend that in cases where the
yield of chromoendoscopy is reduced, such as with a poor preparation, significant
postinflammatory polyps, or significant underlying inflammation, random mucosal
sampling may be indicated.8
Almost all guidelines that endorse chromoendoscopy do so with the caveat “for
appropriately trained endoscopists” or “when the expertise is available.” The New
Zealand Guidelines Group,16 which overall endorses the NICE guidelines for surveil-
lance in IBD, states that chromoendoscopy is not available in New Zealand and
thus was not considered for the guidelines. It is now incumbent on the training pro-
grams and GI professional societies to train endoscopists in the use of chromoendo-
scopy for the optimal detection of polypoid and nonpolypoid neoplasia.9 The main
utility of chromoendoscopy, as stated in the ECCO consensus document, is its ability
to “highlight subtle changes in the architecture of the colonic mucosa,”18 thus
increasing dysplasia detection. Chromoendoscopy can also highlight surface crypt
architectural abnormalities, and has been used to guide management of detected
lesions.44,45 Kudo pit-pattern classification can help to characterize detected lesions
and their surrounding flat mucosa as having neoplastic (Kudo pit pattern III–V) or non-
neoplastic (Kudo pit pattern I or II) architectural changes.46,47 However, inflammation
with regenerative changes can result in Kudo type IIIL or IV pit patterns48 and, although
useful, pit-pattern classification cannot replace histologic evaluation.49
Although long-term data on the outcome of dysplasia detected by chromoendo-
scopy are lacking, the newest guidelines from the BSG, NICE, ECCO, and CCA agree
that chromoendoscopy with targeted biopsies maximizes the yield of surveillance
colonoscopy for dysplasia detection,1,6,8,18 which is currently the goal of IBD surveil-
lance. Additional consensus is needed to determine whether there is a role for random
biopsies or histologic staging biopsies during chromoendoscopy with targeted biopsy
surveillance. Because histologic activity is used to risk-stratify patients in most of the
guidelines, it seems prudent to take several biopsies during surveillance colonoscopy
even if no targeted biopsies are obtained. How many are required, and whether
biopsies should be taken throughout the colon, have yet to be determined.
Guidelines Summary
 The goal of endoscopic surveillance in IBD is to reduce the morbidity and mor-
tality of CRC, by either detecting and resecting dysplasia or detecting CRC at
an earlier, potentially curable stage.
 The most recent European and Australian guidelines suggest that to maximize
the yield of surveillance colonoscopy for dysplasia detection, chromoendoscopy
with targeted biopsies is the surveillance method of choice (Table 3). Random
biopsies of normal-appearing mucosa are of low yield.
 Histologic staging biopsies may be required for risk stratification of patients.
Table 3
Society guidelines for detected dysplasia
Visible Dysplastic Lesion,
Endoscopically Resectable
with Negative Biopsies
from Adjacent Mucosa
Visible Dysplastic Lesion,
Endoscopically Unresectable,
or Biopsies from Adjacent
Mucosa with Dysplasia
Invisible High-Grade
Dypslasia Detected by
Random Biopsies
Invisible Low-Grade Dysplasia Detected by
Random Biopsies
ECCO,18
2013
Surveillance at 3 mo and
then yearly, regardless
of degree of dysplasia
Colectomy Confirm by expert GI pathologist
Rule out visible lesion with repeat
chromoendoscopy surveillance
Colectomy if confirmed
Confirm by expert GI pathologist
Rule out visible lesion with chromoendoscopy
surveillance
Consider colectomy vs intensified surveillance
with random biopsies
CCA,8 2011 Surveillance Colectomy Confirm by expert GI pathologist
Colectomy
Confirm by expert GI pathologist
Mutlifocal: colectomy vs intensified
surveillance at 3–6 mo with
chromoendoscopy, then annually
Unifocal: consider surgery vs surveillance at
6 mo then annually
BSG,1 2010 Surveillance Colectomy Not specifically mentioned Confirm by expert GI pathologist
Consider colectomy vs intensified surveillance
ACG,4 2010 Surveillance Colectomy Confirm by expert GI pathologist
Colectomy
Confirm by expert GI pathologist
Colectomy vs intensified surveillance
AGA,2 2010 Adenoma-like DALM:
surveillance (6 mo)
Non–adenoma-like DALM:
colectomy
Confirm by expert GI pathologist
Colectomy
Confirm by expert GI pathologist
Colectomy vs intensified surveillance
ASGE,5 2006 Surveillance DALM: colectomy Confirm by expert GI pathologist
Colectomy
Confirm by expert GI pathologist
Mutlifocal: colectomy
Unifocal: consider colectomy vs surveillance at
6 mo then annually
CCFA,3 2005 Confirm by expert GI pathologist
Mutlifocal or repetitive: colectomy
Unifocal: colectomy; if patient opts for surveil-
lance, then <6-mo intervals recommended
Abbreviations: ACG, American College of Gastroenterology; AGA, American Gastroenterological Society; ASGE, American Society for Gastrointestinal Endoscopy;
BSG, British Society for Gastroenterology; CCA, Cancer Council of Australia; CCFA, Crohn’s and Colitis Foundation of America; DALM, dysplasia-associated lesion or
mass; ECCO, European Crohn’s and Colitis Organization; GI, gastrointestinal.
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Surveillance of Patients with Colonic IBD 477 In situations where the performance of chromoendoscopy is reduced (eg, poor
preparation, significant postinflammatory polyps, significant underlying inflam-
mation) or expertise is unavailable, multiple random biopsies with targeted
biopsies of white-light detected lesions remains an acceptable alternative.HOW SHOULD DETECTED DYSPLASIA BE MANAGED?
Older guidelines recommended categorizing detected lesions as sporadic adenomas
if found outside an area of known colitis, or as a dysplasia-associated lesion or mass
(DALM) if detected within an area of colitis.9 DALMs were further subcategorized
as adenoma-like, if they were raised lesions with an endoscopic appearance of a
sporadic adenoma, or non–adenoma-like.2 Adenoma-like DALMs were amenable to
endoscopic resection with close follow-up, whereas non–adenoma-like DALMs
were considered an indication for surgery. Colectomy was additionally indicated for
high-grade dysplasia detected by random biopsy, and multifocal low-grade dysplasia
detected on random biopsy.
Long-term follow-up of endoscopically resected raised dysplastic lesions has been
reassuring, with a recent meta-analysis demonstrating a low risk of IBD-CRN following
resection of polypoid dysplasia.50 The use of chromoendoscopy and other image-
enhancing techniques not only enhances dysplasia detection, it can also help to delin-
eate lesion borders and facilitate lesion characterization to determine whether a
detected lesion is endoscopically resectable or not.9,44,45
In this era of image-enhanced endoscopy, a simplified management approach to
detect dysplastic lesions is now recommended. Although the terminology is evolving,
the newest ECCO consensus guidelines recommend characterizing dysplasia as
endoscopically visible or nonvisible.18 Nonvisible dysplasia refers to dysplasia
detected by random biopsy and not associated with an endoscopically visible lesion.
According to these ECCO consensus guidelines, well-circumscribed lesions that
appear to be endoscopically resectable should be completely resected by an experi-
enced endoscopist, regardless of underlying colitis or grade of dysplasia. If complete
resection is achieved with negative biopsies from the flat mucosa immediately adja-
cent to the polypectomy site, and no dysplasia is found elsewhere in the colon, close
endoscopic surveillance, preferably with chromoendoscopy, at 3 months and then at
least annually is appropriate. An unresectable lesion or a lesion with dysplasia in the
adjacent mucosa is an indication for colectomy. If dysplasia is not associated with a
visible lesion, but is found on random biopsy, repeat evaluation with chromoendo-
scopy by an experienced endoscopist is warranted to assess for a visible and resect-
able dysplastic lesion and to evaluate for synchronous dysplasia; in this case, random
biopsies may be indicated.18
These guidelines highlight that the most important feature of well-circumscribed,
detected lesions is endoscopic resectability, with confirmation that adjacent mucosa
is negative for dysplasia. Older guidelines follow similar recommendations using
different terminology.
The definition of endoscopic resectability will continue to evolve. Consensus is
needed to standardize the terminology of detected dysplastic lesions and dysplasia
detected by random biopsies not associated with an endoscopically visible lesion.
Additional consensus is required to determine optimal surveillance after a dysplastic
lesion is resected, and how or if the degree of dysplasia should influence the surveil-
lance interval. While endoscopically invisible high-grade dysplasia is universally
considered an indication for colectomy, the approach to low-grade dysplasia needs
further clarification.
Shergill & Farraye478Guidelines Summary
 Endoscopically visible lesions that are well circumscribed and amenable to
resection, with no evidence of dysplasia in the surrounding mucosa or elsewhere
in the colon on nontargeted biopsies, are appropriate for continued colonoscopic
surveillance.
 Endoscopically invisible high-grade dysplasia, detected by random biopsy
alone, is an indication for colectomy.
 Societies differ in their recommendations for endoscopically invisible low-grade
dysplasia.SUMMARY
Surveillance colonoscopy is indicated in patientswith left-sided or extensive UC, and in
patients with Crohn’s colitis with involvement ofmore than 1 colonic segment. The goal
of surveillance is to detect dysplasia and to prevent IBD-CRN.Risk factors for IBD-CRN
that influence screening and surveillance intervals require further study. To maximize
dysplasia detection, European society guidelines endorse chromoendoscopy with tar-
geted biopsies, although societies in the United States have yet to endorse chromoen-
doscopy as the preferred method for IBD-CRN surveillance. The European guidelines
endorsing chromoendoscopy do not require random biopsies of normal-appearing
colonic mucosa. However, the role of random biopsies for dysplasia detection needs
to be clarified in the setting of inflammation or in areas of pseudopolyps, when the yield
of chromoendoscopy may be decreased. Although histologic staging is important for
the risk stratification of patients in almost all guidelines, the number of biopsies required
and where they should be obtained needs further clarification. Most guidelines agree
that well-circumscribed endoscopically detected dysplasia amenable to resection,
with no evidence of dysplasia in the surrounding mucosa or elsewhere in the colon,
is appropriate for surveillance. However, the definition of endoscopic resectability
will continue to evolve, and consensus is needed for both the terminology and the
approach to endoscopically visible and nonvisible dysplasia.REFERENCES
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